Quote | Ikena Oncology Inc. (NASDAQ:IKNA)
Last: | $1.66 |
---|---|
Change Percent: | 0.0% |
Open: | $1.63 |
Close: | $1.66 |
High: | $1.68 |
Low: | $1.63 |
Volume: | 110,117 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Ikena Oncology Inc. (NASDAQ:IKNA)
2024-05-29 14:38:54 ET More on Mid-day movers & stock Faraday Future Intelligent Electric, Inc. (FFIE) Q4 2023 Earnings Call Transcript Why AST SpaceMobile's Q1 2024 Results Just Squeezed Short-Sellers AST SpaceMobile, Inc. (ASTS) Q1 2024 Earnings Call Transcript...
2024-05-29 14:22:11 ET More on Ikena Oncology Ikena to cut workforce by 53%, explore strategic options (update) Seeking Alpha’s Quant Rating on Ikena Oncology Historical earnings data for Ikena Oncology Financial information for Ikena Oncology ...
Message Board Posts | Ikena Oncology Inc. (NASDAQ:IKNA)
Subject | By | Source | When |
---|---|---|---|
The now | Tartiaboy | investorshub | 05/10/2023 1:10:35 PM |
news all the way baby | crudeoil24 | investorshub | 05/05/2023 2:17:28 PM |
what do you make of this data? | crudeoil24 | investorshub | 04/17/2023 10:13:37 PM |
This is a very inactive board, but IKNA | Tartiaboy | investorshub | 01/29/2023 5:40:26 PM |
znewcar1: IKNA 29% v3,46M c5.37 f36,1M H5.37 EOD pop | znewcar1 | investorshangout | 06/25/2022 2:51:38 AM |
News, Short Squeeze, Breakout and More Instantly...
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (G...
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (G...
Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF mutant cancers BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, In...